CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published ahead of print on November 14, 2007
Clinical Journal of the American Society of Nephrology
© 2007 American Society of Nephrology
doi: 10.2215/CJN.01810407
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.01810407v1
3/1/105    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holden, R. M.
Right arrow Articles by Day, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holden, R. M.
Right arrow Articles by Day, A. G.

Received April 23, 2007
Accepted on October 11, 2007

ORIGINAL ARTICLES

Major Bleeding in Hemodialysis Patients

Rachel M. Holden *1, Gavin J. Harman *, Miao Wang {dagger}, David Holland *, and Andrew G. Day {dagger}

*Division of Nephrology, Queen’s University, and {dagger}Clinical Research Centre, Kingston General Hospital, Kingston, Ontario, Canada


1 To whom correspondence should be addressed. E-mail: holdenr{at}kgh.kari.net.


  Abstract

Background and objectives: Few studies have examined risk factors for hemorrhage in hemodialysis patients. The contribution of warfarin and antiplatelet agent exposure to the incidence of first major bleeding episodes in hemodialysis patients was determined.

Design, setting, participants, & measurements: Retrospective chart review was performed in eligible hemodialysis patients. Incidence rates were determined as the number of first major bleeding events divided by the total exposure time on each treatment combination. Time-dependent covariates and Cox proportional hazard models were used to determine the hazard rate of having a first major bleeding event.

Results: A total of 1028 person-years of exposure were observed from 255 patients with a median follow-up time of 3.6 yr. The incidence rate of major bleeding episodes was 2.5% per person-year. The incidence of major bleeding episodes was 3.1% per person-year of warfarin exposure, 4.4% per person-year of aspirin exposure, and 6.3% per person-year of exposure to the combination of warfarin and aspirin. Compared with patients who were not prescribed warfarin or aspirin, the multivariable hazard ratio for time to first major bleeding event was 3.59 for warfarin, 5.24 for aspirin, and 6.19 for the combination of aspirin and warfarin.

Conclusions: The risk for major bleeding episodes in hemodialysis patients increases significantly while on aspirin and/or warfarin, although warfarin alone did not reach statistical significance. Future studies should evaluate the efficacy of these agents in the secondary prevention of cardiovascular events in this high-risk population.


This article has been cited by other articles:


Home page
 ChestHome page
M. M. Sood, P. Komenda, A. R. Sood, C. Rigatto, and J. Bueti
The Intersection of Risk and Benefit: Is Warfarin Anticoagulation Suitable for Atrial Fibrillation in Patients on Hemodialysis?
Chest, October 1, 2009; 136(4): 1128 - 1133.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. M. Sood, C. Rigatto, J. Bueti, C. Lang, L. Miller, A. PonnamPalam, M. Reslerova, A. Sood, and P. Komenda
Thrice weekly warfarin administration in haemodialysis patients
Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3162 - 3167.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
S. Hiremath, R. M. Holden, D. Fergusson, and D. L. Zimmerman
Antiplatelet Medications in Hemodialysis Patients: A Systematic Review of Bleeding Rates
Clin. J. Am. Soc. Nephrol., August 1, 2009; 4(8): 1347 - 1355.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. E. Chan, J. M. Lazarus, R. Thadhani, and R. M. Hakim
Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients
J. Am. Soc. Nephrol., April 1, 2009; 20(4): 872 - 881.
[Abstract] [Full Text] [PDF]

Home page
 In VivoHome page
T. CHIRAS, E. D. PAPADAKIS, A. KATOPODI, E. CHATZIANESTI, K. FOURTOUNAS, S. PAPAKONSTANTINOU, I. THEODOROPOULOS, A. DAKOURAS, N. ZEREFOS, D. VALIS, et al.
Platelet GP IIIA Polymorphism HPA-1 (PLA1/2) Is Associated with Hypertension as the Primary Cause for End-stage Renal Disease in Hemodialysis Patients from Greece
In Vivo, January 1, 2009; 23(1): 177 - 181.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Society of Nephrology.